JAKK:NASDAQJAKKS Pacific, Inc. Analysis
Data as of 2026-05-19 - not real-time
$21.66
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
JAKKS Pacific trades at $21.66, sitting just below its 20‑day SMA of 22.37 but above the 50‑day SMA of 21.35, suggesting a marginal bullish bias despite a bearish MACD histogram and a neutral RSI of 46.8. The stock is navigating a high 30‑day volatility environment (42%) and a beta of 1.5**, indicating sensitivity to market swings, while volume has been on a downtrend, raising short‑term liquidity concerns. Recent earnings delivered a surprise loss of $0.17 versus the consensus loss of $0.36 (+52% surprise), with international sales jumping 38% even as North American revenue fell 16%, highlighting a shifting sales mix that could support future top‑line recovery.
From a valuation perspective, the company carries a trailing PE of 30.9 but a forward PE of 6.6 thanks to expected earnings upside, and analysts project a target price of $28.5 – roughly a 31% upside from current levels. However, the DCF fair value sits at only $16.36, the dividend yield is attractive at 4.6% but the payout ratio exceeds 140%, calling dividend sustainability into question. Combined with a modest ROE of 3.3% and a debt‑to‑equity ratio above 20, the stock appears fairly valued with a blend of growth and value characteristics, yet it carries elevated sector and market‑risk factors.
From a valuation perspective, the company carries a trailing PE of 30.9 but a forward PE of 6.6 thanks to expected earnings upside, and analysts project a target price of $28.5 – roughly a 31% upside from current levels. However, the DCF fair value sits at only $16.36, the dividend yield is attractive at 4.6% but the payout ratio exceeds 140%, calling dividend sustainability into question. Combined with a modest ROE of 3.3% and a debt‑to‑equity ratio above 20, the stock appears fairly valued with a blend of growth and value characteristics, yet it carries elevated sector and market‑risk factors.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Earnings beat with positive surprise
- Bearish MACD and decreasing volume
- Price near short‑term support at $20.20
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- Analyst target price implying ~31% upside
- Strong international revenue growth
- Forward PE compression to 6.6x
Long Term
> 3 yearsNeutral
Model confidence: 7/10
Key Factors
- Cyclical consumer sector exposure
- High dividend payout ratio undermining sustainability
- Elevated beta and volatility indicating market sensitivity
Key Metrics & Analysis
Financial Health
Revenue Growth-5.80%
Profit Margin1.41%
P/E Ratio30.9
ROE3.34%
ROA1.92%
Debt/Equity20.67
P/B Ratio1.0
Op. Cash Flow$32.0M
Free Cash Flow$13.4M
Technical Analysis
TrendBullish
RSI46.8
Support$20.20
Resistance$24.45
MA 20$22.37
MA 50$21.35
MA 200$18.82
MACDBearish
VolumeDecreasing
Fear & Greed Index89.61
Valuation
Fair Value$16.36
Target Price$28.50
Upside/Downside31.58%
GradeFair
TypeBlend
Dividend Yield4.61%
Risk Assessment
Beta1.52
Volatility42.10%
Sector RiskMedium
Reg. RiskLow
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.